Increased hepatic density and phospholipidosis due to XXXX .

@entity1 @entity2643 @entity1496 @entity358 @entity492 @entity943 @entity493
@entity2643 is an amphiphilic iodinated compound that is used as a treatment for refractory @entity943 . During evaluation for possible @entity358 , a @entity1 receiving @entity2643 was noted to have an increase in the density of his liver as seen on computed tomographic (CT) scanning of the abdomen. Six additional @entity1 who were receiving @entity2643 were subsequently evaluated to ascertain the frequency of this finding. The CT density of the liver was increased in all @entity1 . Values obtained varied from 95 to 145 H, with a mean of 117 +/- 8.9 (normal, 30-70). The alkaline phosphatase was elevated in four @entity1 , but only one had an elevation of either the @entity493 or @entity492 aminotransferase. Two @entity1 underwent liver biopsies, and both revealed membranous lamellar phospholipid-containing structures within hepatocytes. Animal studies done to recreate these findings revealed that @entity2643 accumulated in the liver at concentrations 175-500 times greater than those found in serum. Quantitative measurements of @entity1496 in samples from the same liver showed that the @entity1496 levels were correspondingly elevated. In the treated animals, there was a small but statistically significant increase in the CT density of the liver, whereas the values for untreated animals were unchanged. Treatment with @entity2643 leads to an accumulation in the liver of this iodinated compound and hence an increase in the CT density of the liver. This accumulation of the drug in hepatic lysosomes apparently causes a secondary phospholipidosis.
